PsychoGenics, AstraZeneca To Identify New Treatments For CNS

PsychoGenics and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous System (CNS) disorders.

Under the agreement, PsychoGenics will use its proprietary drug discovery technologies to evaluate a number of AstraZeneca drug candidates for their potential to treat psychiatric disorders.

Reportedly, PsychoGenics will receive research payments and milestones commensurate with the stage of development, as well as royalties on any future sales.

Emer Leahy, president and CEO of PsychoGenics, said: We are excited about this collaboration and look forward to working with AstraZeneca’s scientific team. We are confident that, with AstraZeneca’s compound libraries and expertise in CNS drug discovery and our proprietary drug discovery approach, we have an opportunity to identify novel and improved treatments for serious psychiatric disorders.”